Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14557864 | 0.83 | STAT6 (0.41) | DPP4DPP8CYP2D6DPP9DPP7 | |
| SCHEMBL14557796 | 0.79 | DPP4 (0.48) | DPP4DPP8CYP2D6DPP9DPP7 | |
| SCHEMBL14557815 | 0.75 | DPP4 (0.45) | DPP4DPP8CYP2D6DPP9DPP7 | |
| SCHEMBL14557871 | 0.73 | HCAR3 (0.55) | KDM4E | |
| SCHEMBL14557769 | 0.72 | NPC1 (0.49) | DPP4DPP8DPP9DPP7GAA | |
| SCHEMBL14557743 | 0.72 | HRH3 (0.46) | DPP4POLB | |
| SCHEMBL14557802 | 0.71 | DPP4 (0.47) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14557756 | 0.71 | DPP4 (0.47) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14557767 | 0.71 | NPC1 (0.48) | DPP4DPP8DPP9DPP7GAA | |
| SCHEMBL14557747 | 0.71 | NPSR1 (0.48) | POLBMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | DPP4 288/4885DPP8 2475/4885CYP2D6 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.